May 23, 2011
A federal judge in California on Friday tossed a shareholder class action against XenoPort Inc., saying claims that the company withheld information about problems delaying the approval of restless legs syndrome drug Horizant weren't sufficient and needed to be redrawn.
January 05, 2011
XenoPort Inc. shareholders have lodged a consolidated class action based on two earlier suits claiming the company withheld information that caused federal regulators to block approval of a restless leg syndrome drug it developed with GlaxoSmithKline PLC, allegedly inflating share prices.